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Abstract
Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease associated with major obstetrical complications such as
gestational loss, preterm delivery, fetal growth restriction (FGR) and preeclampsia. Published literature is not consensual regard-
ing the main risk factors for each of these outcomes. Our goal with this study was to determine the most important predictors for
each of the main adverse pregnancy outcomes in this population. We conducted a retrospective cohort study of unifetal preg-
nancies of women with the diagnosis of SLE followed in our unit between January 1994 and December 2016. We excluded
elective terminations of pregnancy and cases lost to follow-up and we analyzed 157 pregnancies (128 women). Multiple logistic
regression models for the outcomes gestational loss, preterm delivery, fetal growth restriction, and preeclampsia were built. Two-
sided p-values of < 0.05 were used to determine statistical significance, and two-sided confidence intervals of 95% are reported.
In our cohort, the main risk factors for gestational loss were maternal age and the presence of antiphospholipid antibodies. Lupic
nephritis was predictive of a preterm delivery and preeclampsia. Renal involvement and lupus flares during pregnancy were risk
factors for FGR. Overall, the main risk factor for an adverse pregnancy outcome were lupus flares during pregnancy. Despite
optimal pregnancy monitoring, women with SLE are still at risk for adverse pregnancy outcomes. Risk stratification for each of
these outcomes is crucial for an effective counselling and tailored monitoring.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic, autoim-
mune disease that can affect every organ and system and usu-
ally follows a relapsing and remitting course. Its prevalence is
estimated around 23.2 cases per 100.000 person-years in
North America. Its incidence is globally rising, possibly due
to the increased awareness for the disease and improvement of
diagnostic tools that allow the detection of milder presenta-
tions of SLE [1]. Females have a higher incidence of SLE
when compared with men, with a sex ratio ranging from 2:1
to 15:1 [1]. In fact, this condition frequently affects women of
childbearing age, suggesting a role for hormonal factors in the
pathogenesis of the disease [2, 3].
SLE has been associated with major maternal, obstetrical,
and neonatal complications. Exacerbation of the disease, ges-
tational loss, preterm delivery, fetal growth restriction (FGR),
preeclampsia, and HELLP syndrome have been described in
pregnant or puerperal SLE patients, and neonatal lupus has
been reported in their offspring [2, 4–6].
Most studies show that the prognosis for the pregnancy is
globally worse when there is renal involvement (often in the
setting of positive antiphospholipid antibodies), although
there appear to be different clinical and laboratorial predictors
for each of the individual adverse pregnancy outcomes [6].
The knowledge of these risk factors is crucial for an effective
counselling and tailoring of fetal and maternal monitoring in
this population.
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Previous studies are not consensual on the predictors for
each of the adverse pregnancy outcomes [4, 7, 8] and some
fail to account for other important risk factors. Our goal with
this study was to determine the key risk factors for each of the
main obstetric adverse pregnancy outcomes in women with
SLE in our cohort.
Patients and Methods
Patient Selection
We conducted a retrospective cohort study of unifetal pregnan-
cies of women with the diagnosis of SLE followed in our obstet-
ric unit of autoimmune diseases between January 1994 and
December 2016. All patients with positive antiphospholipid an-
tibodies were medicated with aspirin and low molecular weight
heparin according to our unit’s guidelines.
From an initial population of 189 pregnancies, we excluded
multiple pregnancies (n = 4), elective termination of pregnan-
cy before 11 weeks (n = 12) and cases lost to follow-up (n =
16) and we analyzed the outcomes of 157 pregnancies (corre-
sponding to 128 women) (Fig. 1).
Clinical Data
Clinical, laboratory, and sonographic data was collected from
individual patient charts.
Definitions
The diagnosis of SLE was confirmed in the patient’s medical
records and classified in terms of target organ affection accord-
ing to the patient history and laboratory data. The date of diag-
nosis and presence of antiphospholipid antibodies (lupus anti-
coagulant, anticardiolipin antibodies, and beta-2-glycoprotein I)
were also obtained through medical records. The patients were
considered to be positive for antiphospholipid antibodies if at
least one of them was present on two or more occasions
12 weeks apart. Anticardiolipin antibodies (IgG and IgM) were
identified with an enzyme-linked immunosorbent assay
(ELISA) [9]. Beta-2-glycoprotein I antibodies were not
routinely measured until 2006, and from that date forward they
were identified with ELISA. Lupus anticoagulant was assessed
by multiple coagulation tests using platelet-poor plasma sam-
ples, following internationally accepted guidelines [10].
A lupus flare was defined as a significant worsening of clin-
ical symptoms or laboratorial measurements. The disease was
considered active in the moment of conception if the last flare
was less than 6 months before the diagnosis of pregnancy.
Gestational loss was defined as either first trimester spon-
taneous abortion or fetal death. Births before 37 weeks of
gestation were classified as preterm. Fetal growth restriction
was diagnosed when estimated fetal weight was below the
10th centile for a given gestational age, associated with
Doppler abnormalities. Preeclampsia was defined as a new-
onset persistent hypertension (blood pressure > 140/
90 mmHg) after 20 weeks of gestation in association with
new-onset proteinuria (300 mg or more of protein in a 24-h
urine collection) or hypertension without proteinuria but asso-
ciated with organ dysfunction: thrombocytopenia, liver dam-
age, new development of renal failure, pulmonary edema, or
new-onset cerebral or visual complaints. HELLP syndrome
was diagnosed in the presence of laboratorial signs of hemo-
lysis, elevated enzyme levels, and low platelet levels. A com-
posite adverse outcome was defined as the presence of one or
more of the following: gestational loss, preterm delivery, pre-
eclampsia, HELLP syndrome, fetal growth restriction, or neo-
natal death.
Statistical Analysis
Continuous data were reported as means and standard devia-
tions. Categorical data were reported as numbers and propor-
tions. Proportions were compared using the chi-square test or
Fisher’s exact test, and means were compared using Student’s
t test. Multiple logistic regressionmodels were used to analyze
the binary outcomes (gestational loss, preterm delivery, fetal
growth restriction, and preeclampsia) controlling for con-
founders. Confounders were selected based on previous liter-
ature, tested and remained in the model based on statistical
significance. Two-sided p-values of < 0.05 are used to deter-
mine statistical significance, and two-sided confidence inter-
vals of 95% are reported.
Exclusion criteria
• Multiple pregnancies (n=4)
• Elective terminations of pregnancy before 11 weeks 
(women’s choice, n=11; medical termination for 
endstage renal disease, n=1)
• Lost to follow up (n= 16)N = 157
N= 189Fig. 1 Patient selection
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Results
The characteristics of our population are summarized in
Table 1. Mean maternal age is 29.6 years, and the majority
of women are nulliparas (61%). The prevalence of chronic
hypertension in our cohort is 14%. Regarding obstetric
history, 10.2% of women have had a previous preterm
birth. The history of any previous gestational loss is re-
markable (43%), the majority of which on the first trimes-
ter (23.1%) but more 10% of women report a history of at
least one second trimester loss.
Regarding SLE, the mean time of disease evolution is
6.8 years (SD 5.4). Approximately 32% of patients have
renal involvement and 25.5% have at least one positive
antiphospholipid antibody. Lupus anticoagulant
is positive in 12.1% of patients and around 23% have
SSA or SSB antibodies. The majority of patients did not
have an active disease in the moment of conception
(90.7%). Lupus flares during pregnancy were reported
in 15 gestations (9.6%).
Concerning the outcomes of pregnancy, mean gestation-
al age at delivery was 37 weeks (SD 2.3) with a mean
neonatal birthweight of 2808.3 g (SD 617). Nine women
had a gestational loss (5.7%). Roughly one-quarter of the
population had a preterm delivery (24.3%). Preeclampsia
complicated 11 pregnancies (7.2%) and we had one case of
HELLP syndrome (0.66%). Fetal growth restriction was
diagnosed in 13.2% of pregnancies. There was one neona-
tal death (0.66%). The overall occurrence of an adverse
pregnancy outcome was 38.9%.
Table 1 Description of the
population N = 157
Maternal characteristics
Maternal age (years), mean (SD) 29.6 (4.7)
Nulliparity 96 (61.1%)
Chronic hypertension 22 (14%)
History of fetal growth restriction 2 (1.3%)
History of preeclampsia 2 (1.3%)
History of preterm delivery 16 (10.2%)
History gestational loss 68 (43.3%)
First trimester 1–3 losses: n = 35 (22.4%; > 3 losses: 1 (0.64%)
Second trimester 1–3 losses: n = 17 (10.8%)
Third trimester 1 loss: n = 2 (1.3%)
Lupus characteristics
Time from diagnosis (years), mean (SD) 6.8 (5.4)
Renal involvement 49 (31.6%)
Active disease in the moment of conception 14 (9.3%)
Presence of one or more antiphospholipid antibodies 40 (25.5%)
Presence of lupus anticoagulant 19 (12.1%)
Presence of anti-SSA or anti-SSB 36 (22.9%)
Lupus flare during pregnancy 15 (9.6%)
Pregnancy outcome
Mean gestation; age at delivery (weeks), mean (SD) 36.9 (2.3%)
Preterm birth 36 (24.3%)
Gestational loss 9 (5.7%)
Preeclampsia 11 (7.2%)
HELLP syndrome 1 (0.66%)




Birth weight (g), mean (SD) 2808.3 (617)
Neonatal death 1 (0.67%)
Composite adverse pregnancy outcome 61 (38.9%)
Values correspond to number of observations-n, and percentage of population (), unless otherwise specified
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Gestational Loss
In pregnancies complicated by gestational loss (Table 2),
women were significantly older when compared with those
without losses (33.7 vs 29.4 years, p < 0.01). They had a more
frequent past history of preterm delivery (44.4% vs 8.1%, p =
0.007) and gestational loss, particularly in the second trimester
(55.6% vs 8.1%, p < 0.01).
These patients had a higher mean time from the diagnosis of
lupus (8.2 vs 6.4 years, p< 0.01) and were more frequently pos-
itive for one or more antiphospholipid antibodies (66.7% vs
23%, p < 0.01) (Table 2).
When testing the influence of time from diagnosis of lupus
in gestational loss in a multiple logistic regression model,
controlling for maternal age and number of previous gesta-
tional losses this association does not seem significant (p =
0.14) (Supplementary Table 1).
On the other hand, in a similar multiple logistic regression
model, the presence of one or more antiphospholipid antibodies
was positively correlated with the occurrence of gestational loss,
even after controlling for maternal age and number of previous
gestational losses, OR= 6.02 (95% CI 1.29; 28.13, p= 0.02).
In conclusion, the risk factors for gestational loss were
maternal age, OR = 1.20 (95%CI 1.01; 1.42) and the presence
of antiphospholipid antibodies, OR = 6.02 (95% CI 1.29;
28.13) (Supplementary Table 2).
Preterm Birth
Women that gave birth before 37 weeks of gestation
(Table 3) were more frequently nullipara (83.3% vs
55.4%, p < 0.01) and had a higher prevalence of chronic
hypertension (30.6% vs 8.9%, p < 0.01) and lupic ne-
phritis (23.6% vs 58.3%, p < 0.01). Their pregnancies
were more frequently complicated by lupus flares
(25% vs 5.4%, p < 0.01).
When testing the association of lupic nephritis and
lupus flares during pregnancy with preterm birth, in a
multiple logistic regression model controlling for previ-
ous preterm birth, nulliparity and chronic hypertension,
the presence of lupic nephritis is significantly correlated
with the occurrence of preterm birth, OR = 4.06 (95%
CI 1.63; 10.12, p < 0.01) while the incidence of lupus
flares during pregnancy is marginally non-significant
(p = 0.06) (Supplementary Table 3).
Therefore, the occurrence of preterm birth is significantly
correlated only with lupic nephritis.
Fetal Growth Restriction
Women with growth restricted fetuses (Table 4) had a
higher prevalence of lupic nephritis (55% vs 27.7%, p =
0.02) and active disease in the moment of conception
Table 2 Maternal characteristics
according to gestational loss Gestational loss
No n = 148 Yes n = 9 p
Maternal characteristics
Maternal age (years), mean (SD) 29.4 (4.49) 33.7 (6.12) 0.007*
Nulliparity 92 (62.2%) 4 (44.4%) 0.311
Chronic hypertension 21 (14.2%) 1 (11.1%) 0.633
History of fetal growth restriction 2 (1.35) 0 (0%) 0.88
History of preeclampsia 2 (1.35) 0 (0%) 0.88
History of preterm delivery 12 (8.1) 4 (44.4%) 0.007*
History of gestational loss
First trimester 35 (23.6%) 1 (11%) 0.08
Second trimester 12 (8.1%) 5 (55.6%) <0.001*
Third trimester 2 (1.3%) 0 (0%) 0.88
Lupus characteristics
Time from diagnosis (years), mean (SD) 6.4 (5.01) 13 (8.21) 0.007*
Renal involvement 47 (32.2%) 2 (22.2%) 0.72
Active disease in the moment of conception 14 (10.5%) 0 (0%) 0.47
Presence of one or more antiphospholipid antibodies 34 (23%) 6 (66.7%) 0.009*
Presence of lupus anticoagulant 16 (10.8%) 3 (33.3%) 0.079
Presence of anti-SSA or anti-SSB 35 (23.7%) 1 (11.1%) 0.69
Lupus flare during pregnancy 15 (10.1%) 0 (0%) 0.60
Values correspond to number of observations - n, and percentage of population (), unless otherwise specified
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(28.6% vs 8.2%, p = 0.04). Their pregnancies were more
frequently complicated by lupus flares (35% vs 6%,
p < 0.01).
When analyzing the association between fetal growth
restriction (FGR) and lupic nephritis, active disease in
the moment of conception and lupus flares during preg-
nancy, controlling for chronic hypertension, both renal
involvement, OR = 5.60 (95% CI 1.23; 23.60, p = 0.02)
and lupic flares during pregnancy, OR = 4.78 (95% CI
1.08; 21.08, p = 0.04) were significantly associated with
the outcome. The presence of an active disease in the
moment of conception was marginally non-significant
(p = 0.06) (Supplementary Table 4).
In conclusion, renal involvement and lupus flares during
pregnancy were risk factors for FGR.
Preeclampsia
In pregnancies complicated by preeclampsia (Table 5), wom-
en appear to be younger (25.3 vs 29.9 years, p < 0.01) and
more frequently nulliparas (81.8% vs 59.6%, p < 0.20).
These women have a higher prevalence of lupic nephritis
(81.8% vs 27.3%, p < 0.01).
After controlling for maternal age, nulliparity and chronic
hypertension in a logistic regression model, the positive asso-
ciation between lupic nephritis and preeclampsia remained,
OR = 29.78 (95% CI 3.84; 281.11, p < 0.01) (Supplementary
Table 5).
Composite Adverse Pregnancy Outcome
Women whose pregnancy was complicated by gestation-
al loss, preterm delivery, preeclampsia, HELLP syn-
drome, fetal growth restriction, or neonatal death
(Table 6) were more frequently nulliparas (73.8% vs
53.1%, p = 0.01). They had a higher prevalence of lupic
nephritis (42.6% vs 24.5%, p = 0.02) and a higher inci-
dence of lupus flares during pregnancy (19.7% vs 3.1%,
p < 0.01).
After controlling for maternal age, chronic hyperten-
sion, nulliparity, number of previous gestational losses
and history of prematurity, a strong positive association
between lupus flares during pregnancy and the compos-
ite pregnancy outcome remained OR = 4.72 (95% CI
1.20; 18.63, p = 0.03) while the association between this
outcome and lupic nephritis was not significant (p =
0.11) (Supplementary Table 6).
Discussion
Gestational loss (encompassing early pregnancy loss and
fetal demise) is described in up to 22% of SLE patients [4].
Table 3 Maternal characteristics
according to preterm delivery Preterm delivery
No n = 112 Yes n = 36 p
Maternal characteristics
Maternal age (years), mean (SD) 29.7 (4.66) 28.3 (3.81) 0.12
Nulliparity 62 (55.4%) 30 (83.3%) 0.003*
Chronic hypertension 10 (8.9%) 11 (30.6%) 0.004*
History of fetal growth restriction 1(0.89%) 1(2.78%) 0.429
History of preeclampsia 2 (1.79%) 0 (0%) 0.571
History of preterm delivery 11(9.82%) 1(2.78%) 0.467
History of gestational loss
First trimester 29 (25,89%) 6 (16,67%) 0.605
Second trimester 10 (8.93%) 2 (5.56%) 1.00
Third trimester 2 (1.79%) 0 (0%) 1.00
Lupus characteristics
Time from diagnosis (years), mean (SD) 6.17 (5.16) 7.25 (4.50) 0.267
Renal involvement 26(23.64%) 21(58.33%) < 0.001*
Active disease in the moment of conception 10 (9.9%) 4 (12.12%) 0.746
Presence of one or more antiphospholipid antibodies 26 (23.2%) 8 (22.2%) 1.00
Presence of lupus anticoagulant 13 (11.6%) 3 (8.33%) 0.762
Presence of anti-SSA or anti-SSB 30 (26.8%) 5 (13.9%) 0.175
Lupus flare during pregnancy 6 (5.4%) 9 (25%) 0.002*
Values correspond to number of observations - n, and percentage of population (), unless otherwise specified
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Table 4 Maternal characteristics
according to fetal growth
restriction
Fetal growth restriction
No n = 132 Yes n = 20 p
Maternal characteristics
Maternal age (years), mean (SD) 29.80 27.75 0.068
Nulliparity 79 (59.9%) 14 (70%) 0.466
Chronic hypertension 17 (12.9%) 5 (25%) 0.172
History of fetal growth restriction 1 (0.76%) 1 (5%) 0.247
History of preeclampsia 1 (0.76%) 1 (5%) 0.247
History of preteen delivery 13 (9.9%) 3 (15%) 0.445
History of gestational loss
First trimester 34 (25.8%) 2 (10%) 0.162
Second trimester 17 (12.9%) 0 (0%) 0.130
Third trimester 2 (1.5%) 0 (0%) 1.00
Lupus characteristics
Time from diagnosis (years), mean (SD) 6.86 (5.68) 5.78 (2.82) 0.431
Renal involvement 36 (27.7%) 11 (55%) 0.020*
Active disease in the moment of conception 10 (8.2%) 4 (28.6%) 0.039*
Presence of one or more antiphospholipid antibodies 34 (25.8%) 4 (20%) 0.783
Presence of lupus anticoagulant 16 (12.1%) 1 (5%) 0.701
Presence of anti-SSA or anti-SSB 32 (24.2%) 4 (20%) 0.785
Lupus flare during pregnancy 8 (6.0%) 7 (35%) 0.001*
Values correspond to number of observations - n, and percentage of population (), unless otherwise specified
Table 5 Maternal characteristics
according to preeclampsia Preeclampsia
No n = 141 Yes n = 11 p
Maternal characteristics
Maternal age (years), mean (SD) 29.9 (4.67) 25.3 (2.61) 0.0016*
Nulliparity 84 (59.6%) 9 (81.8%) 0.204
Chronic hypertension 19 (13.5%) 3 (27.3%) 0.200
History of fetal growth restriction 2 (1.42%) 0 (0%) 1.00
History of preeclampsia 2 (1.42%) 0 (0%) 1.00
History of preterm delivery 16 (11.4%) 0 (0%) 0.607
History of gestational loss
First trimester 34 (24.8%) 1 (9.1%) 0.460
Second trimester 16 (11.4%) 1 (9.1%) 1.00
Third trimester 2 (1.4%) 0 (0%) 1.00
Lupus characteristics
Time from diagnosis (years), mean (SD) 6.7 (5.6) 7.4 (3.4) 0.643
Renal involvement 38 (27.3%) 9 (81.8%) 0.001*
Active disease in the moment of conception 12 (9.5%) 2 (20%) 0.274
Presence of one or more antiphospholipid antibodies 35 (24.8%) 3 (27.3%) 1.00
Presence of lupus anticoagulant 1702.1%) 0 (0%) 0.613
Presence of anti-SSA or anti-SSB 34 (24.1%) 2 (18.2%) 1.00
Lupus flare during pregnancy 14 (9.9) 1 (9.1) 1.00
Values correspond to number of observations - n, and percentage of population (), unless otherwise specified
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Some studies identify the presence of antiphospholipid
antibodies (anticardiolipin antibodies, lupus anticoagu-
lant and beta-2-glycoprotein I antibodies) as the main
determinants for this outcome, particularly if there is
multiple positivity or positivity for lupus anticoagulant
[5] although there are some conflicting results [11].
Lupus activity in the moment of conception and disease
flares were also suggested as important risk factors for
this outcome [7, 12]. Moreover, the presence of SSA/Ro
or SSB/La antibodies is a known cause of fetal com-
plete atrioventricular heart block and fetal demise, par-
ticularly in the third trimester [5]. In our cohort, the
overall incidence of gestational loss was much lower
than expected (5.7%). We can hypothesize that differen-
tial loss to follow-up (16 cases) and scheduling of the
first pregnancy appointment for a gestational age after
the occurrence of a miscarriage, might explain this find-
ing, since these women frequently choose to cancel their
appointments after a pregnancy loss. The main risk fac-
tors for gestational loss were maternal age and the pres-
ence of one or more antiphospholipid antibodies, con-
cordantly with previous studies. However, lupus activity
in the moment of conception, disease flares during preg-
nancy and the presence of anti-SSA/SSB antibodies
were not important risk factors after controlling for
maternal age and number of previous gestational losses.
We can hypothesize that this difference is due to the
lack of adjustment for obstetric confounders in previous
studies [7, 12]. We also cannot exclude that the small
number of events (n = 9) compromises our power to
detect a significant association.
The incidence of preterm birth is increased in women with
SLE, with meta-analysis reporting rates as high as 34.9% [13].
In previous studies, the main predictor for this outcome ap-
pears to be lupus activity during pregnancy, with the preterm
birth rate increasing two-thirds in women with mild-to-severe
disease activity during pregnancy [8]. In our cohort, disease
flares during gestation were a significant risk factor for pre-
term delivery in the univariate analysis. However, this associ-
ation was not significant after controlling for the presence of
lupus nephritis. On the other hand, renal involvement had a
significant association with the outcome, both in the univari-
ate analysis and in the multivariate model. In fact, the litera-
ture reports that lupus flares are more frequent when there is
renal involvement [8] and in our cohort this seems to be the
main driver for preterm delivery.
Fetal growth restriction is described in approximately 13%
of pregnancies of women with SLE [14]. We found the exact
same incidence in our cohort. Although its pathogenesis in the
setting of SLE is not completely clear, the existence of
Table 6 Maternal characteristics
according to composite adverse
pregnancy outcome
Composite adverse pregnancy outcome
No n = 96 Yes n = 61 p
Maternal characteristics
Maternal age (years), mean (SD) 29.9 (4.9) 29.1 (4.4) 0.297
Nulliparity 51 (53.1%) 45 (73.8%) 0.012*
Chronic hypertension 9 (9.4%) 13 (21.3%) 0.057
History of fetal growth restriction 1 (1.0%) 1 (1.6%) 1.00
History of preeclampsia 1(1.0%) 1(1.6%) 1.00
History of preterm delivery 9 (9.4%) 7 (11.5%) 0.788
History of gestational loss
First trimester 26(27.1%) 10(16.4%) 0.172
Second trimester 8 (8.3%) 9 (14.8%) 0.292
Third trimester 2(2.1%) 0 (0%) 0.522
Lupus characteristics
Time from diagnosis (years), mean (SD) 6.3 (5.4) 7.6 (5.3) 0.159
Renal involvement 23 (24.5%) 26 (42.6%) 0.022*
Active disease in the moment of conception 8 (9.0%) 6 (11.5%) 0.771
Presence of one or more antiphospholipid antibodies 20 (20.8%) 20 (32.8%) 0.132
Presence of lupus anticoagulant 10 (10.4%) 9 (14.8%) 0.457
Presence of anti-SSA or anti-SSB 26 (27.1%) 10 (16.4%) 0.172
Lupus flare during pregnancy 3 (3.1%) 12 (19.7%) 0.001*
Values correspond to number of observations - n, and percentage of population (), unless otherwise specified
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clinical/subclinical inflammation and the use of some medica-
tions during pregnancy were suggested as possible causal fac-
tors [15]. In our cohort, both renal involvement and lupus
flares during pregnancy were significant risk factors for this
outcome, which seems to highlight the role of inflammation in
this pathway.
Preeclampsia rates are two-to-three fold increased in preg-
nancies with SLE [15]. This disorder has been associated with
conditions that impair endothelial function, such as lupus ne-
phritis [15]. Consistently with previous studies, in our cohort
the presence of lupus nephritis was a significant risk factor for
preeclampsia, after controlling for known confounders.
Interestingly, a younger maternal age was also associated with
an increased risk for preeclampsia in our cohort, contrary from
the general population where older patients have a higher risk
for this condition. We can hypothesize that in younger women
there would be a higher prevalence of juvenile onset SLE,
which is associated with worse outcomes [16]. However, we
do not have the data in our records to test for that hypothesis.
Overall, the main risk factor for an adverse pregnancy out-
come (gestational loss, preterm delivery, preeclampsia,
HELLP syndrome, fetal growth restriction, or neonatal death)
was the occurrence of lupus flares during pregnancy. This is
consistent with previous reports [17] and highlights the im-
portance of close monitoring of these pregnancies as well as
the need to maintain adequate immunosuppression during this
stage in order to minimize adverse outcomes.
Our study has some limitations inherent to a retrospective
study design, namely the poor information regarding maternal
medication use. The incidence of preeclampsia (n = 11) and
gestational loss (n = 9) was low in our cohort, which decreases
our power to detect significant associations with predictors,
specifically in a multiple regression model. In addition, our
cohort encompasses a vast period from 1994 to 2016. During
this time frame, there were multiple advances in diagnostic
criteria and medication use during pregnancy, changing the
outcomes of the disease.
In conclusion, despite pregnancy monitoring in a special-
ized center, women with SLE are still considerably at risk for
adverse pregnancy outcomes. This study provides a compre-
hensive analysis of the most important risk factors for the
main adverse pregnancy outcomes after controlling for impor-
tant confounders, which is often lacking in the literature.
Overall, it can contribute to a better tailoring of obstetric sur-
veillance of these pregnancies.
Compliance with Ethical Standards
Conflict of Interest The authors declare that there are no conflicts of
interest.
Ethical Approval This was a retrospective, observational study that in
our institution did not require specific ethics approval.
Informed Consent This was a retrospective, observational study that in
our institution, did not require specific informed consent.
References
1. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W (2017) The
worldwide incidence and prevalence of systemic lupus erythema-
tosus: a systematic review of epidemiological studies.
Rheumatology (Oxford) 56(11):1945–1961
2. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW (2007)
Reproductive and menopausal factors and risk of systemic lupus
erythematosus in women. Arthritis Rheum 56(4):1251–1262
3. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Parks CG,
Gilkeson GS (1998) Hormonal, environmental, and infectious risk
factors for developing systemic lupus erythematosus. Arthritis
Rheum 41(10):1714–1724
4. Lateef A, Petri M (1994) Systemic lupus erythematosus and preg-
nancy. Rheum Dis Clin N Am 20(1):87–118
5. Clowse MEB, Jamison M, Myers E, James AH (2008) A national
study of the complications of lupus in pregnancy. Am J Obstet
Gynecol 199(2):127.e1–127.e6
6. Peart E, Clowse MEB (2014) Systemic lupus erythematosus and
pregnancy outcomes: an update and review of the literature. Curr
Opin Rheumatol 26(2):118–123
7. Liu J, Zhao Y, Song Y, Zhang W, Bian X, Yang J, Liu D, Zeng X,
Zhang F (2012) Pregnancy in women with systemic lupus erythe-
matosus: a retrospective study of 111 pregnancies in Chinese wom-
en. J Matern Fetal Neonatal Med 25(3):261–266
8. Jara LJ, Medina G, Cruz-Dominguez P, Navarro C, Vera-Lastra O,
Saavedra MA (2014) Risk factors of systemic lupus erythematosus
flares during pregnancy. Immunol Res 60(2–3):184–192
9. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni
P, Boffa MC (2004) Minimal requirements for antiphospholipid
antibodies ELISAs proposed by the European forum on
antiphospholipid antibodies. Thromb Res 114(5–6):553–558
10. Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the
diagnosis of lupus anticoagulant. ThrombHaemost 74(04):1185–1190
11. Gayed M, Gordon C (2007 Nov 1) Pregnancy and rheumatic dis-
eases. Rheumatology (Oxford) 46(11):1634–1640
12. Ko HS, Ahn HY, Jang DG, Choi S-K, Park Y-G, Park IY, Lee G,
Park SH, Shin JC (2011) Pregnancy outcomes and appropriate
timing of pregnancy in 183 pregnancies in Korean patients with
SLE. Int J Med Sci 8(7):577–583
13. Uramoto KM, Michet CJ, Thumboo J, Sunku J, O’Fallon WM,
Gabriel SE (1999) Trends in the incidence andmortality of systemic
lupus erythematosus, 1950-1992. Arthritis Rheum 42(1):46–50
14. Smyth A, Oliveira GHM, Lahr BD, Bailey KR, Norby SM,Garovic
VD (2010) A systematic review and meta-analysis of pregnancy
outcomes in patients with systemic lupus erythematosus and lupus
nephritis. Clin J Am Soc Nephrol 5(11):2060–2068
15. Ostensen M, Clowse M (2013) Pathogenesis of pregnancy compli-
cations in systemic lupus erythematosus. Curr Opin Rheumatol
25(5):591–596
16. Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW,
Isenberg DA (2016) Differences in disease phenotype and severity
in SLE across age groups. Lupus. 25(14):1542–1550
17. ClowseMEB,Magder LS,Witter F, Petri M (2005 Feb) The impact
of increased lupus activity on obstetric outcomes. Arthritis Rheum
52(2):514–521
Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Clinic Rev Allerg Immunol (2020) 59:287–294294
